Ganesh Kini, MD
Internal Medicine · Conyers, GANPI 1881652519
Payments from drug & device makers
Across 322 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$612
- Johnson & Johnson$490
- Novo Nordisk$488
- Daiichi Sankyo Inc.$350
- Pfizer$307
- Merck$300
- plus $3K from 28 others
What the payments were for
- Speaking & faculty fees$701%
- Food & beverage$5,23098%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 28 | $612 |
| Johnson & Johnson | 39 | $490 |
| Novo Nordisk | 49 | $488 |
| Daiichi Sankyo Inc. | 18 | $350 |
| Pfizer | 20 | $307 |
| Merck | 20 | $300 |
| Amarin Pharma, Inc. | 8 | $269 |
| AbbVie(2 entities) | 22 | $251 |
| Lilly USA, LLC | 12 | $250 |
| GSK | 14 | $249 |
| Sanofi-aventis U.S. LLC | 15 | $221 |
| Boehringer Ingelheim | 10 | $170 |
| Abbott | 2 | $139 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $133 |
| Amgen | 6 | $131 |
| Bayer | 7 | $131 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $86 |
| Insulet Corporation | 3 | $85 |
| Astellas Pharma US Inc | 4 | $72 |
| Sanofi | 1 | $70 |
| Otsuka America Pharmaceutical, Inc. | 4 | $59 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Novartis | 3 | $55 |
| Sunovion Pharmaceuticals Inc. | 9 | $54 |
| Exact Sciences | 3 | $49 |
| Esperion Therapeutics, Inc. | 3 | $48 |
| Eisai Inc. | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $37 |
| Spine Wave, Inc. | 1 | $34 |
| Ultragenyx Pharmaceutical Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $16 |
| Dexcom, Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vascepa$140
- FARXIGA$126
- FreeStyle Libre Pro$124
- EUCRISA$105
How this compares
$5,323 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Soliqua 100-33Insulin Glargine/Lixisenatide | 66 | $72,774 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 84 | $60,730 |
| KerendiaFinerenone | 56 | $49,420 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $44,886 |
| EliquisApixaban | 35 | $42,744 |
| XareltoRivaroxaban | 48 | $39,879 |
| Xigduo XrDapaglifloz Propaned/Metformin | 35 | $36,691 |
| MounjaroTirzepatide | 30 | $34,241 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 36 | $27,750 |
| OzempicSemaglutide | 23 | $26,436 |
| MyrbetriqMirabegron | 42 | $26,397 |
| LinzessLinaclotide | 26 | $22,535 |
| FarxigaDapagliflozin Propanediol | 16 | $15,072 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $14,559 |
| JanuviaSitagliptin Phosphate | 14 | $11,554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimTrijardy Xr, Synjardy Xr | $170 | $88,480120 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $221 | $72,77466 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $249 | $52,88574 claims |
| BayerKerendia | $131 | $49,42056 claims |
| PfizerEliquis | $307 | $42,74435 claims |
| Johnson & JohnsonXarelto | $490 | $39,87948 claims |
| Lilly USA, LLCMounjaro | $250 | $34,24130 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $612 | $29,63137 claims |
| Novo NordiskOzempic | $488 | $26,43623 claims |
| Astellas Pharma US IncMyrbetriq | $72 | $26,39742 claims |
| AbbVieLinzess | $251 | $22,53526 claims |
| MerckJanuvia | $300 | $11,55414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Conyers
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.